

Francesco Panzuto

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/8516759/francesco-panzuto-publications-by-year.pdf>

Version: 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

103
papers

3,242
citations

30
h-index

55
g-index

149
ext. papers

3,863
ext. citations

3.6
avg, IF

4.64
L-index

#	Paper	IF	Citations
103	Role of [F]FDG PET/CT in the management of G1 gastro-entero-pancreatic neuroendocrine tumors.. <i>Endocrine</i> , 2022 , 1	4	1
102	Association of Upfront Peptide Receptor Radionuclide Therapy With Progression-Free Survival Among Patients With Enteropancreatic Neuroendocrine Tumors.. <i>JAMA Network Open</i> , 2022 , 5, e220290 ^{10.4}	10.4	0
101	Prognostic significance of laterality in lung neuroendocrine tumors.. <i>Endocrine</i> , 2022 , 1	4	0
100	What Gastroenterologists Should Know about Carcinoid Syndrome. <i>Gastroenterology Insights</i> , 2022 , 13, 127-138	2.1	1
99	Bone Metastases in Neuroendocrine Tumors: Molecular Pathogenesis and Implications in Clinical Practice. <i>Neuroendocrinology</i> , 2021 , 111, 207-216	5.6	6
98	MYC Upregulation Confers Resistance to Everolimus and Establishes Vulnerability to Cyclin-Dependent Kinase Inhibitors in Pancreatic Neuroendocrine Neoplasm Cells. <i>Neuroendocrinology</i> , 2021 , 111, 739-751	5.6	5
97	Synoptic reporting of echocardiography in carcinoid heart disease (ENETS Carcinoid Heart Disease Task Force). <i>Journal of Neuroendocrinology</i> , 2021 , e13060	3.8	6
96	Risk of preoperative understaging of duodenal neuroendocrine neoplasms: a plea for caution in the treatment strategy. <i>Journal of Endocrinological Investigation</i> , 2021 , 44, 2227-2234	5.2	3
95	Sporadic non-functioning pancreatic neuroendocrine tumours: multicentre analysis. <i>British Journal of Surgery</i> , 2021 , 108, 811-816	5.3	4
94	Comparison of Endoscopic Techniques in the Management of Type I Gastric Neuroendocrine Neoplasia: A Systematic Review. <i>Gastroenterology Research and Practice</i> , 2021 , 2021, 6679397	2	1
93	Reply to Dr. Hall and coworkers. <i>Expert Opinion on Drug Safety</i> , 2021 , 20, 865-866	4.1	
92	Octreotide long-acting release (LAR) in combination with other therapies for treatment of neuroendocrine neoplasia: a systematic review. <i>Journal of Gastrointestinal Oncology</i> , 2021 , 12, 845-855	2.8	0
91	Assessing safety and activity of cabozantinib combined with lanreotide in gastroenteropancreatic (GEP) and thoracic neuroendocrine tumors (NETs): The phase II LOLA trial.. <i>Journal of Clinical Oncology</i> , 2021 , 39, TPS4167-TPS4167	2.2	
90	Second primary neoplasms in patients with lung and gastroenteropancreatic neuroendocrine neoplasms: Data from a retrospective multi-centric study. <i>Digestive and Liver Disease</i> , 2021 , 53, 367-374 ^{3.3}	3.3	3
89	Impact of the SARS-CoV2 pandemic dissemination on the management of neuroendocrine neoplasia in Italy: a report from the Italian Association for Neuroendocrine Tumors (Itanet). <i>Journal of Endocrinological Investigation</i> , 2021 , 44, 989-994	5.2	6
88	[F]FDG-PET/CT and long-term responses to everolimus in advanced neuroendocrine neoplasia. <i>Journal of Endocrinological Investigation</i> , 2021 , 44, 811-818	5.2	1
87	Efficacy of Lutetium-Peptide Receptor Radionuclide Therapy in Inducing Prolonged Tumour Regression in Small-Bowel Neuroendocrine Tumours: A Case of Favourable Response to Retreatment after Initial Objective Response. <i>Oncology Research and Treatment</i> , 2021 , 44, 276-280	2.8	

86 Treatment of Intestinal NETs (Including Appendix) **2021**, 201-210

85	Efficacy and safety of high-dose lanreotide autogel in patients with progressive pancreatic or midgut neuroendocrine tumours: CLARINET FORTE phase 2 study results. <i>European Journal of Cancer</i> , 2021 , 157, 403-414	7.5	9
84	Tumor Heterogeneity in Gastro-Entero-Pancreatic Neuroendocrine Neoplasia. <i>Endocrines</i> , 2021 , 2, 28-36	0.8	2
83	Gastroenteropancreatic Neuroendocrine Neoplasms in Patients with Inflammatory Bowel Disease: An ECCO CONFER Multicentre Case Series. <i>Journal of Crohn's and Colitis</i> , 2021 ,	1.5	1
82	Perioperative Chemotherapy in Poorly Differentiated Neuroendocrine Neoplasia of the Bladder: A Multicenter Analysis. <i>Journal of Clinical Medicine</i> , 2020 , 9,	5.1	1
81	SARS-CoV2 RNA detection in a pancreatic pseudocyst sample. <i>Pancreatology</i> , 2020 , 20, 1011-1012	3.8	32
80	Theranostic Designed Near-Infrared Fluorescent Poly (Lactic-co-Glycolic Acid) Nanoparticles and Preliminary Studies with Functionalized VEGF-Nanoparticles. <i>Journal of Clinical Medicine</i> , 2020 , 9,	5.1	6
79	Occurrence of exocrine pancreatic insufficiency in patients with advanced neuroendocrine tumors treated with somatostatin analogs. <i>Pancreatology</i> , 2020 , 20, 875-879	3.8	10
78	Radiopharmaceuticals for Breast Cancer and Neuroendocrine Tumors: Two Examples of How Tissue Characterization May Influence the Choice of Therapy. <i>Cancers</i> , 2020 , 12,	6.6	3
77	Biliary Stone Disease in Patients with Neuroendocrine Tumors Treated with Somatostatin Analogs: A Multicenter Study. <i>Oncologist</i> , 2020 , 25, 259-265	5.7	9
76	Surgery with Radical Intent: Is There an Indication for G3 Neuroendocrine Neoplasms?. <i>Annals of Surgical Oncology</i> , 2020 , 27, 1348-1355	3.1	26
75	CT texture analysis of liver metastases in PNETs versus NPNETs: Correlation with histopathological findings. <i>European Journal of Radiology</i> , 2020 , 124, 108812	4.7	7
74	Gastro-entero-pancreatic neuroendocrine neoplasia: The rules for non-operative management. <i>Surgical Oncology</i> , 2020 , 35, 141-148	2.5	6
73	Management of Asymptomatic Sporadic Nonfunctioning Pancreatic Neuroendocrine Neoplasms (ASPEN) ≤ cm: Study Protocol for a Prospective Observational Study. <i>Frontiers in Medicine</i> , 2020 , 7, 598438	4.9	7
72	Morphological Factors Related to Nodal Metastases in Neuroendocrine Tumors of the Appendix: A Multicentric Retrospective Study. <i>Annals of Surgery</i> , 2020 , 271, 527-533	7.8	27
71	Nonconventional Doses of Somatostatin Analogs in Patients With Progressing Well-Differentiated Neuroendocrine Tumor. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020 , 105,	5.6	14
70	The ENETS TNM staging and grading system accurately predict prognosis in patients with rectal NENs. <i>Digestive and Liver Disease</i> , 2019 , 51, 1725-1730	3.3	5
69	Tumour type and size are prognostic factors in gastric neuroendocrine neoplasia: A multicentre retrospective study. <i>Digestive and Liver Disease</i> , 2019 , 51, 1456-1460	3.3	18

68	Role of Combined [Ga]Ga-DOTA-SST Analogues and [F]FDG PET/CT in the Management of GEP-NENs: A Systematic Review. <i>Journal of Clinical Medicine</i> , 2019 , 8,	5.1	34
67	Multidisciplinary Management of Neuroendocrine Neoplasia: A Real-World Experience from a Referral Center. <i>Journal of Clinical Medicine</i> , 2019 , 8,	5.1	17
66	Prognostic impact of tumour burden in stage IV neuroendocrine neoplasia: A comparison between pancreatic and gastrointestinal localizations. <i>Pancreatology</i> , 2019 , 19, 1067-1073	3.8	7
65	Sunitinib in patients with pre-treated pancreatic neuroendocrine tumors: A real-world study. <i>Pancreatology</i> , 2018 , 18, 198-203	3.8	14
64	Therapy for Locoregional Disease: Stomach/Duodenum, Colon/Rectum 2018 , 219-234		
63	Metformin Use Is Associated With Longer Progression-Free Survival of Patients With Diabetes and Pancreatic Neuroendocrine Tumors Receiving Everolimus and/or Somatostatin Analogues. <i>Gastroenterology</i> , 2018 , 155, 479-489.e7	13.3	36
62	A classification prognostic score to predict OS in stage IV well-differentiated neuroendocrine tumors. <i>Endocrine-Related Cancer</i> , 2018 , 25, 607-618	5.7	13
61	Prognosis of sporadic resected small (≤1cm) nonfunctional pancreatic neuroendocrine tumors - a multi-institutional study. <i>Hpb</i> , 2018 , 20, 251-259	3.8	57
60	Heterogeneity of Duodenal Neuroendocrine Tumors: An Italian Multi-center Experience. <i>Annals of Surgical Oncology</i> , 2018 , 25, 3200-3206	3.1	23
59	Clinical Usefulness of F-Fluorodeoxyglucose Positron Emission Tomography in the Diagnostic Algorithm of Advanced Entero-Pancreatic Neuroendocrine Neoplasms. <i>Oncologist</i> , 2018 , 23, 186-192	5.7	29
58	Competitive Testing of the WHO 2010 versus the WHO 2017 Grading of Pancreatic Neuroendocrine Neoplasms: Data from a Large International Cohort Study. <i>Neuroendocrinology</i> , 2018 , 107, 375-386	5.6	52
57	Stage IV Gastro-Entero-Pancreatic Neuroendocrine Neoplasms: A Risk Score to Predict Clinical Outcome. <i>Oncologist</i> , 2017 , 22, 409-415	5.7	25
56	Everolimus as first line therapy for pancreatic neuroendocrine tumours: current knowledge and future perspectives. <i>Journal of Cancer Research and Clinical Oncology</i> , 2017 , 143, 1209-1224	4.9	8
55	Functional Imaging in the Follow-Up of Enteropancreatic Neuroendocrine Tumors: Clinical Usefulness and Indications. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017 , 102, 1486-1494	5.6	22
54	Prognostic impact of the cumulative dose and dose intensity of everolimus in patients with pancreatic neuroendocrine tumors. <i>Cancer Medicine</i> , 2017 , 6, 1493-1499	4.8	9
53	Everolimus in Pancreatic Neuroendocrine Carcinomas G3. <i>Pancreas</i> , 2017 , 46, 302-305	2.6	37
52	Lack of Association for Reported Endocrine Pancreatic Cancer Risk Loci in the PANDoRA Consortium. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2017 , 26, 1349-1351	4	4
51	Evaluation of the Relationships Between Computed Tomography Features, Pathological Findings, and Prognostic Risk Assessment in Gastrointestinal Stromal Tumors. <i>Journal of Computer Assisted Tomography</i> , 2017 , 41, 271-278	2.2	12

50	Impact of Ki67 re-assessment at time of disease progression in patients with pancreatic neuroendocrine neoplasms. <i>PLoS ONE</i> , 2017 , 12, e0179445	3.7	29
49	Antiproliferative effect of somatostatin analogs in advanced gastro-entero-pancreatic neuroendocrine tumors: a systematic review and meta-analysis. <i>Oncotarget</i> , 2017 , 8, 46624-46634	3.3	18
48	Risk and Protective Factors for Small Intestine Neuroendocrine Tumors: A Prospective Case-Control Study. <i>Neuroendocrinology</i> , 2016 , 103, 531-7	5.6	18
47	Functional imaging tests and CT scan: Detection of new metastases and clinical usefulness in digestive neuroendocrine neoplasms follow-up.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 219-219	2.2	
46	A Case of Pancreatic Small Cell Neuroendocrine Carcinoma Associated With SIADH. <i>Pancreas</i> , 2016 , 45, e20-2	2.6	1
45	Digestive neuroendocrine neoplasms: A 2016 overview. <i>Digestive and Liver Disease</i> , 2016 , 48, 829-35	3.3	14
44	The role of combined Ga-DOTANOC and (18)FDG PET/CT in the management of patients with pancreatic neuroendocrine tumors. <i>Neuroendocrinology</i> , 2014 , 100, 293-9	5.6	44
43	Real-world study of everolimus in advanced progressive neuroendocrine tumors. <i>Oncologist</i> , 2014 , 19, 966-74	5.7	66
42	Acute fulminant hepatitis E virus genotype 3e infection: description of the first case in Europe. <i>Scandinavian Journal of Infectious Diseases</i> , 2014 , 46, 727-31		20
41	Advanced digestive neuroendocrine tumors: metastatic pattern is an independent factor affecting clinical outcome. <i>Pancreas</i> , 2014 , 43, 212-8	2.6	38
40	Radiolabelled somatostatin analogue treatment in gastroenteropancreatic neuroendocrine tumours: factors associated with response and suggestions for therapeutic sequence. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2013 , 40, 1197-205	8.8	44
39	Risk factors for disease progression in advanced jejunoileal neuroendocrine tumors. <i>Neuroendocrinology</i> , 2012 , 96, 32-40	5.6	44
38	Malignant pancreatic neuroendocrine tumour: lymph node ratio and Ki67 are predictors of recurrence after curative resections. <i>European Journal of Cancer</i> , 2012 , 48, 1608-15	7.5	122
37	Ki-67 grading of nonfunctioning pancreatic neuroendocrine tumors on histologic samples obtained by EUS-guided fine-needle tissue acquisition: a prospective study. <i>Gastrointestinal Endoscopy</i> , 2012 , 76, 570-7	5.2	136
36	Oesophageal GIST: MDCT findings of two cases and review of the literature. <i>Journal of Gastrointestinal Cancer</i> , 2012 , 43, 481-5	1.6	6
35	Novel molecular targets for the treatment of gastroenteropancreatic endocrine tumors: answers and unsolved problems. <i>International Journal of Molecular Sciences</i> , 2012 , 14, 30-45	6.3	6
34	Molecular pathology and genetics of pancreatic endocrine tumours. <i>Journal of Molecular Endocrinology</i> , 2012 , 49, R37-50	4.5	58
33	Type I gastric carcinoids: a prospective study on endoscopic management and recurrence rate. <i>Neuroendocrinology</i> , 2012 , 95, 207-13	5.6	78

32	Metastatic and locally advanced pancreatic endocrine carcinomas: analysis of factors associated with disease progression. <i>Journal of Clinical Oncology</i> , 2011 , 29, 2372-7	2.2	216
31	Pancreatic endocrine tumors: improved TNM staging and histopathological grading permit a clinically efficient prognostic stratification of patients. <i>Modern Pathology</i> , 2010 , 23, 824-33	9.8	338
30	Acute leukaemia following low dose peptide receptor radionuclide therapy for an intestinal carcinoid. <i>Digestive and Liver Disease</i> , 2010 , 42, 457-8	3.3	5
29	Clinical relevance of the expression of somatostatin receptors in digestive endocrine tumours. <i>Digestive and Liver Disease</i> , 2010 , 42, 173-4	3.3	3
28	Nasogastric or nasointestinal feeding in severe acute pancreatitis. <i>World Journal of Gastroenterology</i> , 2010 , 16, 3692-6	5.6	20
27	Risk factors for sporadic pancreatic endocrine tumors: a case-control study of prospectively evaluated patients. <i>American Journal of Gastroenterology</i> , 2009 , 104, 3034-41	0.7	39
26	Somatostatin receptor subtypes 2 and 5 are associated with better survival in well-differentiated endocrine carcinomas. <i>Neuroendocrinology</i> , 2009 , 89, 223-30	5.6	41
25	Molecular target therapy for gastroenteropancreatic endocrine tumours: biological rationale and clinical perspectives. <i>Critical Reviews in Oncology/Hematology</i> , 2009 , 72, 110-24	7	32
24	Phenotype expression in a case of adult cystic fibrosis caused by an extremely rare compound heterozygous genotype (2183AA>G/2789+5G>A). <i>Pancreas</i> , 2009 , 38, 599-601	2.6	1
23	Prognostic factors at diagnosis and value of WHO classification in a mono-institutional series of 180 non-functioning pancreatic endocrine tumours. <i>Annals of Oncology</i> , 2008 , 19, 903-8	10.3	177
22	Rhabdomyolysis due to severe hypokaliemia in a Crohn's disease patient after budesonide treatment. <i>Digestive and Liver Disease</i> , 2007 , 39, 776-9	3.3	5
21	Src family kinase activity regulates adhesion, spreading and migration of pancreatic endocrine tumour cells. <i>Endocrine-Related Cancer</i> , 2007 , 14, 111-24	5.7	48
20	Long-term clinical outcome of somatostatin analogues for treatment of progressive, metastatic, well-differentiated entero-pancreatic endocrine carcinoma. <i>Annals of Oncology</i> , 2006 , 17, 461-6	10.3	98
19	Gene expression profiles of progressive pancreatic endocrine tumours and their liver metastases reveal potential novel markers and therapeutic targets. <i>Endocrine-Related Cancer</i> , 2006 , 13, 541-58	5.7	89
18	Corpus-predominant gastritis as a risk factor for false-negative 13C-urea breath test results. <i>Alimentary Pharmacology and Therapeutics</i> , 2006 , 24, 1453-60	6.1	18
17	Endocrine tumours of the stomach. <i>Baillieres Best Practice and Research in Clinical Gastroenterology</i> , 2005 , 19, 659-73	2.5	56
16	Peanut-like 1 (septin 5) gene expression in normal and neoplastic human endocrine pancreas. <i>Neuroendocrinology</i> , 2005 , 81, 311-21	5.6	15
15	Prognostic factors and survival in endocrine tumor patients: comparison between gastrointestinal and pancreatic localization. <i>Endocrine-Related Cancer</i> , 2005 , 12, 1083-92	5.7	317

14	Gastric neuroendocrine tumors. <i>Neuroendocrinology</i> , 2004 , 80 Suppl 1, 16-9	5.6	34
13	Large hiatal hernia in patients with iron deficiency anaemia: a prospective study on prevalence and treatment. <i>Alimentary Pharmacology and Therapeutics</i> , 2004 , 19, 663-70	6.1	37
12	Utility of combined use of plasma levels of chromogranin A and pancreatic polypeptide in the diagnosis of gastrointestinal and pancreatic endocrine tumors. <i>Journal of Endocrinological Investigation</i> , 2004 , 27, 6-11	5.2	82
11	Somatostatin receptor subtypes: basic pharmacology and tissue distribution. <i>Digestive and Liver Disease</i> , 2004 , 36 Suppl 1, S8-16	3.3	22
10	Unlabelled somatostatin analogues in treatment of digestive endocrine tumours. <i>Digestive and Liver Disease</i> , 2004 , 36 Suppl 1, S42-7	3.3	3
9	Can patient characteristics predict the outcome of endoscopic evaluation of iron deficiency anemia: a multiple logistic regression analysis. <i>Gastrointestinal Endoscopy</i> , 2004 , 59, 766-71	5.2	46
8	Intragastric ascorbic but not uric acid is depleted in relation with the increased pH in patients with atrophic body gastritis and H. pylori gastritis. <i>Helicobacter</i> , 2003 , 8, 300-6	4.9	21
7	Symptom-based approach to colorectal cancer: survey of primary care physicians in Italy. <i>Digestive and Liver Disease</i> , 2003 , 35, 869-75	3.3	21
6	Abdominal tuberculosis with pancreatic involvement: a case report. <i>Digestive and Liver Disease</i> , 2003 , 35, 283-7	3.3	7
5	Co-existence of hyperparathyroidism, hypergastrinaemia and multiple gastric carcinoids is not always due to incomplete expression of the MEN-1 syndrome. <i>Digestive and Liver Disease</i> , 2003 , 35, 585-9	3.3	4
4	Staging of digestive endocrine tumours using helical computed tomography and somatostatin receptor scintigraphy. <i>Annals of Oncology</i> , 2003 , 14, 586-91	10.3	24
3	Iron deficiency anemia caused by nonspecific (idiopathic) small bowel ulceration: an uncommon presentation of an uncommon disease. <i>Canadian Journal of Gastroenterology & Hepatology</i> , 2002 , 16, 855-9		7
2	Digestive neuroendocrine tumours: diagnosis and treatment in Italy. A survey by the Oncology Study Section of the Italian Society of Gastroenterology (SIGE). <i>Digestive and Liver Disease</i> , 2001 , 33, 217-21	3.3	24
1	Long-term octreotide treatment of metastatic carcinoid tumor. <i>Annals of Oncology</i> , 2000 , 11, 491-3	10.3	12